4-Methylthioamphetamine
| Clinical data | |
|---|---|
| Other names | 4-MTA; MTA; para-Methylthioamphetamine; p-Methylthioamphetamine | 
| Legal status | |
| Legal status | 
  | 
| Identifiers | |
  | |
| CAS Number | 
  | 
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C10H15NS | 
| Molar mass | 181.30 g·mol−1 | 
| 3D model (JSmol) | |
  | |
  | |
| (what is this?) (verify) | |
4-Methylthioamphetamine (4-MTA), also known as para-methylthioamphetamine (MTA), is a designer drug of the substituted amphetamine class developed in the 1990s by a team led by David E. Nichols, an American pharmacologist and medical chemist, at Purdue University. It acts as a non-neurotoxic highly selective serotonin releasing agent (SSRA) in animals. 4-MTA is the methylthio derivative of amphetamine.